Results 61 to 70 of about 12,370 (174)
Design of Nanocarriers for Kidney Targeted Delivery of Nucleic Acid Therapeutics
Macromolecular Bioscience, Volume 26, Issue 7, July 2026.Nucleic acid therapeutics have been investigated to expand their applications to renal genetic disorders. This review summarizes key considerations in the design and fabrication of nanocarriers for the systemic delivery of nucleic acid therapeutics to the kidneys.
Jun Hyuk Lee +3 more
wiley +1 more source
BMC Nephrology, 2019 Autosomal Dominant Polycystic Kidney Disease (ADPKD) is thought to affect about 1 in 1000 people in the UK. ADPKD causes a progressive decline in kidney function, with kidney failure tending to occur in middle age.
Jan Dudley +11 more
doaj +1 more source
Transplant Infectious Disease, Volume 28, Issue 4, July/August 2026.Among 346 liver transplant recipients, rural residence conferred a 3.3‐fold higher risk of cryptococcal infection — a novel finding suggesting environmental exposure or healthcare access barriers may drive susceptibility. Triple immunosuppression and longer waitlist duration were additional risk factors, with very early infection carrying the worst ...
Rachel Sigler +11 more
wiley +1 more source
Severe parental phenotype associates with hypertension in children with ADPKD.
, 2023 Early detection of hypertension in children with autosomal polycystic kidney disease (ADPKD) may be beneficial, but screening children at risk of ADPKD remains controversial.
Nathalie Demoulin +15 more
core +1 more source
European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants. [PDF]
, 2020 Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterized by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations.
core +2 more sources
Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline. [PDF]
PLoS ONE, 2014 Autosomal dominant polycystic kidney disease (ADPKD) is clinically heterogenic. Biomarkers are needed to predict prognosis and guide management. We aimed to profile microRNA (miRNA) in ADPKD to gain molecular insight and evaluate biomarker potential ...
Iddo Z Ben-Dov +6 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra +4 more
wiley +1 more source
Clinical Transplantation, Volume 40, Issue 6, June 2026.ABSTRACT Background Pneumocystis jirovecii is an opportunistic fungus responsible for Pneumocystis pneumonia (PJP) in hosts with impaired cell‐mediated immunity, particularly solid organ transplant recipients. The aim of our study was to identify risk factors associated with PJP in kidney transplant recipients (KTRs).
Solenne Hulot +9 more
wiley +1 more source
Drugs in Context, 2015 Background: Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder characterized by the development of numerous kidney cysts that result in kidney failure.
Christopher M Blanchette +7 more
doaj +1 more source
Internal Medicine Journal, Volume 56, Issue 6, Page 966-975, June 2026.Abstract Background Chronic kidney disease (CKD) is a significant public health challenge in Australia, affecting ~10% of the adult population and contributing to substantial morbidity and mortality. Diabetes, hypertension, cardiovascular disease and CKD frequently co‐exist; therefore, a multidisciplinary approach is necessary to manage these ...
M. P. Schlaich +7 more
wiley +1 more source